Indaptus Therapeutics (NASDAQ:INDP) Trading Up 6.3% – Still a Buy?

Indaptus Therapeutics, Inc. (NASDAQ:INDP)’s share price rose 6.3% during mid-day trading on Tuesday . The stock traded as high as $1.03 and last traded at $1.01. Approximately 9,030 shares traded hands during trading, a decline of 57% from the average daily volume of 21,207 shares. The stock had previously closed at $0.95.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Maxim Group cut their price target on shares of Indaptus Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Indaptus Therapeutics in a research report on Wednesday, October 16th.

Indaptus Therapeutics Price Performance

The business has a 50 day simple moving average of $1.02 and a 200-day simple moving average of $1.45. The stock has a market capitalization of $10.30 million, a price-to-earnings ratio of -0.59 and a beta of 1.47.

Indaptus Therapeutics (NASDAQ:INDP) last posted its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.15. As a group, equities analysts predict that Indaptus Therapeutics, Inc. will post -1.79 earnings per share for the current year.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.